ralph weichselbaum
University of Chicago
H-index: 169
North America-United States
Description
ralph weichselbaum, With an exceptional h-index of 169 and a recent h-index of 74 (since 2020), a distinguished researcher at University of Chicago, specializes in the field of radiotherapy metastasis.
His recent articles reflect a diverse array of research interests and contributions to the field:
Biology of Blood and Marrow Transplantation
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites
Reconciling the Discrepancies in Randomized Data of Combining Immunotherapy and Radiation Therapy: Not all Radiotherapy is Created Equal
Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy
All-trans retinoic acid enhances radiotherapy and overcomes immune suppression for cancer therapy
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
An integrated clinical-molecular classification of colorectal liver metastases: a biomarker analysis of the randomized phase III new EPOC trial
Professor Information
University | University of Chicago |
---|---|
Position | professor radiation oncology |
Citations(all) | 109454 |
Citations(since 2020) | 27922 |
Cited By | 128652 |
hIndex(all) | 169 |
hIndex(since 2020) | 74 |
i10Index(all) | 895 |
i10Index(since 2020) | 389 |
University Profile Page | University of Chicago |
Research & Interests List
radiotherapy metastasis
Top articles of ralph weichselbaum
Biology of Blood and Marrow Transplantation
For patients with relapsed or refractory classical Hodgkin lymphoma (cHL), salvage chemotherapy followed by consolidation with autologous stem cell transplant (ASCT) remains the standard of care. Even with this aggressive treatment strategy, 5-year progression-free survival is 50%, and there remains interest in maintenance strategies to improve long-term disease-free survival. Lenalidomide is an immunomodulatory agent with demonstrated activity in multiple subtypes of lymphoma including cHL, and has also been shown to improve both progressionfree and overall survival as maintenance therapy after ASCT in multiple myeloma. This multicenter study evaluated maintenance lenalidomide after ASCT for patients with cHL. Patients were enrolled 60 to 90 days post-transplant and received oral lenalidomide on days 1 to 28 of 28-day cycles for a maximum of 18 cycles. Lenalidomide was started at 15 mg daily and increased to maximum of 25 mg daily if tolerated. The primary objective of this study was to assess the feasibility of this regimen, with a goal< 30% rate of discontinuation at or before cycle 12 for drug-related reasons. Twenty-seven patients were enrolled and 26 received at least 1 dose of lenalidomide. With a median follow-up of 51.3 months (range, 12.2 to 76.2 months), 23 of 26 patients were alive. Median eventfree survival was 9.4 months and median progression-free survival had not been reached, with 17 of 26 patients (65.4%) remaining in remission at last follow-up. Excluding 4 patients who discontinued therapy for progression and 2 who discontinued due to noncompliance, the discontinuation rate at or before cycle 12 was 52 …
Authors
Lauren Shea,Marcus P Watkins,Fei Wan,Amanda F Cashen,Nina D Wagner-Johnston,Meagan A Jacoby,Camille N Abboud,John F Dipersio,David D Hurd,Samantha M Jaglowski,Nancy L Bartlett,Todd A Fehniger
Published Date
2020
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites
Purpose: Radiotherapy (RT) is a widely employed anti-cancer treatment. Emerging evidence suggests that RT can elicit both tumor-inhibiting and tumor-promoting immune effects. This study is to investigate immune suppressive factors of radiotherapy. Experimental Design: We used a heterologous two-tumor model in which adaptive concomitant immunity was eliminated. Results: Through analysis of PD-L1 expression and MDSC frequencies using patient PBMC and murine two-tumor and metastasis model, we report that local irradiation can induce a systemic increase in MDSCs, as well as PD-L1 expression on DCs and myeloid cells, and thereby increase the potential for metastatic dissemination in distal, non-irradiated tissue. In a mouse model using two distinct tumors, we found that PD-L1 induction by ionizing radiation (IR) was dependent on elevated chemokine CXCL10 signaling. Inhibiting PD-L1 or …
Authors
Yuzhu Hou,Kaiting Yang,Liangliang Wang,Jiaai Wang,Xiaona Huang,Andras Piffko,Sean Z Luo,Xinshuang Yu,Enyu Rao,Carlos Martinez,Jason Bugno,Matthias Mack,Everett E Vokes,Sean P Pitroda,Steven J Chmura,Ralph R Weichselbaum,Hua Laura Liang
Journal
Clinical Cancer Research
Published Date
2024/3/1
Reconciling the Discrepancies in Randomized Data of Combining Immunotherapy and Radiation Therapy: Not all Radiotherapy is Created Equal
It remains highly unclear and debatable whether combining radiotherapy (RT) and immune checkpoint blocker (ICB) therapy yields improved outcomes compared to either modality alone. Whereas some randomized data have shown improved outcomes, others have not. As a result of these conflicting data, it is essential to reconcile differences in the data and postulate reasons thereof. This work seeks to address these discrepancies, and uses the lessons learned from both positive and negative trials, including the most cutting-edge data available, in order to guide future clinical trial design and clarify the ideal/expected role of combinatorial therapy going forward. Because RT offers two distinct contributions (cytoreductive (local) effects & immune-stimulating (systemic) effects), RT should complement immunotherapy by addressing immunotherapy-resistant clones, and immunotherapy should complement RT by …
Authors
Joe Y Chang,Vivek Verma,Ralph R Weichselbaum
Journal
European Journal of Cancer
Published Date
2024/2/28
Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy
Blockade of programmed cell death-1/programmed cell death-ligand 1 (PD-L1) immune checkpoints with monoclonal antibodies has shown great promise for cancer treatment, but these antibodies can cause immune-related adverse events in normal organs. Here we report a dual-cell targeted chemo-immunotherapeutic nanoscale coordination polymer (NCP), OxPt/BP, comprising oxaliplatin (OxPt) and 2-bromopalmitic acid (BP), for effective downregulation of PD-L1 expression in both cancer cells and dendritic cells (DCs) by inhibiting palmitoyl acyltransferase DHHC3. OxPt/BP efficiently promotes DC maturation by increasing intracellular oxidative stress and enhancing OxPt-induced immunostimulatory immunogenic cancer cell death. Systemic administration of OxPt/BP reduces the growth of subcutaneous and orthotopic colorectal carcinoma by facilitating the infiltration and activation of cytotoxic T lymphocytes …
Authors
Jing Liu,Xiaomin Jiang,Youyou Li,Kaiting Yang,Ralph R Weichselbaum,Wenbin Lin
Journal
ACS nano
Published Date
2024/1/29
All-trans retinoic acid enhances radiotherapy and overcomes immune suppression for cancer therapy
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC (= O)\C= C (/C)\C= C\C= C (/C)\C= C\C1= C (C) CCCC1 (C) C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title claims abstract description 236
Published Date
2024/1/4
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy
The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti‐Warburg effect of Er sensitizes tumor cells to Cu‐mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death‐ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative …
Authors
Youyou Li,Jing Liu,Yimei Chen,Ralph R Weichselbaum,Wenbin Lin
Journal
Advanced Science
Published Date
2024/3/13
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse rate remains high. We conducted a single-center, phase 1, modified 3 + 3 dose-escalation study of the feasibility of combining intensity-modulated total marrow irradiation (IM-TMI) with fludarabine and melphalan for conditioning. Between December 2015 and May 2020, 21 patients with relapsed hematologic disease undergoing second or greater allo-SCT were treated with IM-TMI doses of 6 Gy, 9 Gy, or 12 Gy. Dose-limiting toxicity was defined as a grade 3 or higher treatment-related adverse event; mucositis was the primary dose-limiting toxicity. The median times to neutrophil and platelet engraftment were 10 and 18 days, respectively. The 1-year cumulative incidence of graft-versus-host disease was 65% (95 …
Authors
Misha C Tran,Yasmin Hasan,Amy Wang,Kamil Yenice,Julien Partouche,Wendy Stock,Richard A Larson,Satyajit Kosuri,James L LaBelle,Justin Kline,Peter A Riedell,Andrew S Artz,Ralph Weichselbaum,Michael R Bishop,Bulent Aydogan,Hongtao Liu
Journal
Blood Advances
Published Date
2023/2/14
An integrated clinical-molecular classification of colorectal liver metastases: a biomarker analysis of the randomized phase III new EPOC trial
Objective: We independently validate these molecular subtypes in the randomized, controlled 59 phase III New EPOC trial 60
Authors
Rohan Katipally,Carlos Martinez,Siân A Pugh,John Bridgewater,John Primrose,Enric Domingo,Timothy Maughan,Mark S Talamonti,Mitchell Posner,Ralph Weichselbaum,Sean Pitroda
Journal
JAMA Oncology
Published Date
2023/5/14
Professor FAQs
What is ralph weichselbaum's h-index at University of Chicago?
The h-index of ralph weichselbaum has been 74 since 2020 and 169 in total.
What are ralph weichselbaum's top articles?
The articles with the titles of
Biology of Blood and Marrow Transplantation
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites
Reconciling the Discrepancies in Randomized Data of Combining Immunotherapy and Radiation Therapy: Not all Radiotherapy is Created Equal
Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy
All-trans retinoic acid enhances radiotherapy and overcomes immune suppression for cancer therapy
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
An integrated clinical-molecular classification of colorectal liver metastases: a biomarker analysis of the randomized phase III new EPOC trial
...
are the top articles of ralph weichselbaum at University of Chicago.
What are ralph weichselbaum's research interests?
The research interests of ralph weichselbaum are: radiotherapy metastasis
What is ralph weichselbaum's total number of citations?
ralph weichselbaum has 109,454 citations in total.
What are the co-authors of ralph weichselbaum?
The co-authors of ralph weichselbaum are John B. Little, David Spriggs, Mark Ferguson, George T.Y. Chen, A.J. Mundt, Stephen Kron.